Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control

por Ray, Kausik K., Ginsberg, Henry N., Davidson, Michael H., Pordy, Robert, Bessac, Laurence, Minini, Pascal, Eckel, Robert H., Cannon, Christopher P.
Publicado 2016

Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia

por Kastelein, John J.P., Kereiakes, Dean J., Cannon, Christopher P., Bays, Harold E., Minini, Pascal, Lee, L. Veronica, Maroni, Jaman, Farnier, Michel
Publicado 2017

The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD

por Perrone, Ronald D., Hariri, Ali, Minini, Pascal, Ahn, Curie, Chapman, Arlene B., Horie, Shigeo, Knebelmann, Bertrand, Mrug, Michal, Ong, Albert C.M., Pei, York P.C., Torres, Vicente E., Modur, Vijay, Gansevoort, Ronald T.
Publicado 2022

Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial

por Schiffmann, Raphael, Cox, Timothy M, Dedieu, Jean-François, Gaemers, Sebastiaan J M, Hennermann, Julia B, Ida, Hiroyuki, Mengel, Eugen, Minini, Pascal, Mistry, Pramod, Musholt, Petra B, Scott, David, Sharma, Jyoti, Peterschmitt, M Judith
Publicado 2022

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Pl...

por Peterschmitt, M. Judith, Saiki, Hidemoto, Hatano, Taku, Gasser, Thomas, Isaacson, Stuart H., Gaemers, Sebastiaan J.M., Minini, Pascal, Saubadu, Stéphane, Sharma, Jyoti, Walbillic, Samantha, Alcalay, Roy N., Cutter, Gary, Hattori, Nobutaka, Höglinger, Günter U., Marek, Kenneth, Schapira, Anthony H.V., Scherzer, Clemens R., Simuni, Tanya, Giladi, Nir, Sardi, Sergio Pablo, Fischer, Tanya Z.
Publicado 2022